
Developing Next Generation Gene Therapies
Splice Bio appoints Jean-Philippe Combal as Chairman of the Board of Directors
BARCELONA, January 21, 2021 – Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed Jean-Philippe Combal as Chairman of its Board of Directors. Dr. Combal is a proven senior executive and biotechnology entrepreneur with 30 years of experience in the pharma & biotech industry and particularly in the field of gene therapy.
Splice Bio announces research funding by Cystic Fibrosis Foundation to develop novel AAV vectors
BARCELONA, December 10, 2020 – Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a research agreement with the Cystic Fibrosis Foundation to develop novel adeno-associated viruses (AAVs) aimed at treating people suffering from cystic fibrosis (CF). The Company will receive up to $343,000 in research funding to advance its proprietary 3rd-generation intein platform and develop novel AAVs better suited to target specific cells in the lungs of people with CF.
ProteoDesign announces new investment led by YSIOS Capital and rebrands as Splice Bio
- ProteoDesign rebrands as Splice Bio to develop novel gene therapies based on its proprietary intein technology.
- This pioneering platform has the potential to target genetic diseases that cannot be addressed with current gene therapies.
- Ysios and Asabys join the board of directors as new investors
BARCELONA, September 15, 2020 – Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a new investment into the Company led by Ysios Capital and joined by Asabys Partners from its fund Sabadell Asabys. This financing round was organized thanks to the support of existing shareholder Caixa Capital Risc. ProteoDesign is rebranding as Splice Bio to reflect on its progress with its proprietary intein platform, based on pioneering research by the company’s co-founders, and its new focus on gene therapy.
Private investors



Public Funding


Public Funding

Public Funding

Certification

Tel. +34 93 402 04 56
© Splice Bio
info@splice.bio